BAJAJ BROKING

Notification
No new Notification messages
Inventurus Knowledge Solutions IPO is Open!
Apply for the Inventurus Knowledge Solutions IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Sai Life Sciences Ltd

Healthcare

Offer Period :

11th to 13th Dec 2024

Sai Life Sciences Ltd IPO Details

IPO Date 11th to 13th Dec 2024 Minimum Investment ₹14823 / 1 Lots
Listing Date 2024-12-18 Maximum Investment ₹192699 / 13 Lots
Face Value ₹1 per share Total Issue Size ₹3042.62 Crores
Price ₹522 to ₹549 per share Fresh Issue ₹950 Crores
Lot Size 1 Lots (27 Shares) Offer For Sale ₹ 2092.62
Listing At BSE, NSE Retail Discount ₹ 0
Employee Discount ₹0 per share    
IPO Date 11th to 13th Dec 2024
Listing Date 2024-12-18
Face Value ₹1 per share
Price ₹522 to ₹549 per share
Lot Size 1 Lots (27 Shares)
Listing At BSE, NSE
Employee Discount ₹0 per share
Minimum Investment ₹14823 / 1 Lots
Maximum Investment ₹192699 / 13 Lots
Total Issue Size ₹3042.62 Crores
Fresh Issue ₹950 Crores
Offer For Sale
Retail Discount ₹ 0

About Sai Life Sciences Ltd

Sai Life Sciences Limited has been at the forefront of innovation in small-molecule new chemical entities since its inception in January 1999. Catering to biotech firms and global pharmaceutical companies, the company offers tailored research, development, and manufacturing services. In the financial year 2024 and as of September 30, Sai Life Sciences provided services to over 280 innovator pharmaceutical companies, including 18 of the world’s top 25 pharma giants based on 2023 revenue. Operating across key markets such as the US, UK, Europe, and Japan, the company is backed by a skilled business development team with a global presence.

With a workforce of 3,135 employees as of September 30, 2024, including 2,353 scientific staff with advanced degrees (302 Ph.D.s and 1,475 master's degrees), Sai Life Sciences delivers excellence across the CRDMO value chain. The company’s offerings include contract research and development manufacturing (CRDMO) services, integrated discovery capabilities spanning biology, chemistry, and drug metabolism, and a robust CDMO platform supporting both commercial and developmental molecules. Its commitment to providing end-to-end solutions, combined with a strong focus on innovation, positions Sai Life Sciences as a trusted partner in the pharmaceutical industry.

Timeline

Important dates for allocation and IPO listing.

11th Dec

IPO Starts

13th Dec

IPO Ends

16th Dec

Allotment Date

17th Dec

Initiation of Refund

17th Dec

Credit of Shares to Demat Account

18th Dec

IPO Listing Date

Shareholder Pattern

  Pre-Issue Post-Issue
Promoter Group 41.46 35.24
Public Group 58.54 64.76

Sai Life Sciences Ltd IPO Reservation

QIB Shares Offered 11084225(20%)
NII (HNI) Shares Offered 8313168(15%)
Retail Shares Offered 19397392(35%)
Anchor Investor Shares Offered 16626337(30%)
Total Shares Offered 55421124
Total Shares With Anchor Investor 55421124

IPO Lot Size

ApplicationLotsSharesAmount
Retail (Min)---
Retail (Max)---
S-HNI (Min)---
S-HNI (Max)---

Sai Life Sciences Ltd IPO Registrar

KFin Techologies Ltd
Phone Number +91 40 6716 2222
Email Id einward.ris@kfintech.com
Our Website www.kfintech.com

Sai Life Sciences Ltd IPO Lead Manager

1. Kotak Mahindra Capital Company Ltd

2. IIFL Securities Ltd

3. Jefferies India Pvt Ltd

4. Morgan Stanley India Company Pvt Ltd

Explore IPOs


Explore comprehensive IPO details for every IPO. Access essential information such as listing price, listing date, issue price, lot size, issue size, minimum investment, and IPO timeline. Gain insights into the company's background, strengths, and potential risks. Track the subscription status and delve into the financials of the company, empowering yourself with crucial data for informed investment decisions. Stay ahead in the dynamic IPO market by staying informed on upcoming, ongoing, and past IPOs. 
 

Stay ahead in the ever-evolving IPO landscape with our comprehensive platform. We offer a holistic resource, ensuring you not only access essential details but also gain valuable insights into market trends. Navigate confidently, armed with intricate analyses, expert opinions, and real-time updates. Whether you're a seasoned investor or a novice, our user-friendly interface and extensive information empower you to make well-informed decisions. Experience the convenience of having a dedicated space where you can delve into the intricacies of IPOs, enabling a strategic and calculated approach to the dynamic stock market. 

Sai Life Sciences Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid No. of subscribed
Qualified Institutional Buyers (QIBs) 1,10,84,225 3,54,74,166 19.0
Non Institutional Investors (NIIs) 83,13,168 53,86,743 3,393.0
Non Institutional Investors (Bid amount of more than Ten Lakh Rupees) 55,42,113 34,77,708 2,81,305.0
Non Institutional Investors (Bid amount of more than Two Lakh and upto Ten Lakh Rupees) 27,71,056 19,09,035 2,81,305.0
Retail Individual Investors (RIIs) 1,93,97,392 87,76,377 1,31,375.0
Total 3,87,94,785 4,96,37,286 2,81,305.0

Strength of Sai Life Sciences Ltd

1. One of the largest integrated Indian CRDMOs in terms of revenue from operations for the Financial Year 2024, acting as a one-stop platform for discovery, development and manufacturing.

2. CDMO platform with a diverse mix of commercial and under-development molecules.

3. Fast-growing, integrated Discovery capabilities with focus on biology, chemistry and DMPK services.

4. Long-standing relationship with a diverse base of existing and new customers.

5. Modern R&D infrastructure with a differentiated delivery model and strong regulatory track-record.

6. Experienced management team and Board supported by a qualified scientific talent pool.

7. Strategic business investments with improving profitability metrics.

Risks Involved

1. Its financial performance depends on the company's ability to secure business from biotechnology and pharmaceutical customers and consequently its may be subject to risks, uncertainties and trends that affect the company customers in these industries over which the company has no control.

2. Its business may be adversely affected by a failures to develop or manufacture commercially viable drugs, including for reasons that are not within the company control.

3. The company may not be able to continue to serve its customers if the company fails to meet their standards in audits and inspections and this could significantly harm its reputation and result in the termination of ongoing projects by its customers.

4. The company depends on its research and development activities generally for the company future growth and its inability to achieve the desired outcomes in the company research and development activities may result in customers opting to discontinue their partnerships with it.

5. The company is subject to extensive government regulation, and if the company fails to obtain, maintain or renew its statutory and regulatory licenses, permits and approvals required to operate the company's business, results of operations and cash flows may be adversely affected.

6. Manufacturing interruptions or delays could affect its ability to meet customer demand and lead to higher costs.

7. The company generated a revenue of Rs.6,542.20 million and Rs.14,386.02 million for the six months period ended September 30, 2024 and year ended March 31, 2024 respectively from customers outside India, amounting to 97.40% and 97.95% of total revenue from contract research, development and manufacturing activities, respectively. Furthermore, The company is subject to risks associated with conducting business internationally, and any operational delays and/or additional financial burdens may affect its business and results of operations.

8. Its largest customer contributed 8.00% and 9.55% of the total revenue from operation for the six months period ended September 30, 2024 and the year ended March 31, 2024 respectively. The potential loss of major customers or any of its large contracts could materially and adversely affect the company's business, financial condition and results of operations.

9. The company conduct animal testing, which can result in adverse publicity liability and other issues, including potential disruption to its facilities as a result of protests against animal testing.

10. Its subsidiary, Sai Life Sciences Inc. has incurred losses of Rs.45.66 million, Rs.150.60 million, Rs.125.97 million and Rs.93.10 million for the six months period ended September 30, 2024 and the Financial Years ended March 31, 2024, March 31, 2023 and March 31, 2022, respectively, and it may also incur losses in the future, which may adversely impact its business and the value of the Equity Shares.

Why should you invest in

-

Financials

Particulars For the financial year ending (in ₹ million)
  2024 2023
Total Assets 2275.14 2186.65
Total Liabilities 2275.14 2186.65
Total Expenses 1385.04 1228.7
Total Revenue 
1494.27 1245.1
Profit After Tax 82.81 9.99
EBITDA 314.58 192.9
Adjusted EBITDA 0 0

Sai Life Sciences Ltd IPO Listing Details

Listing Date BSE Script Code NSE Symbol ISIN Final Issue Price
2024-12-18 0 -
INE570L01029
₹0 per share

Listing Day Trading Information

Price Details BSE NSE
Final Issue Price ₹522 ₹0
Open ₹0 ₹0
Low ₹0 ₹0
High ₹0 ₹0
Low ₹0 ₹0

Industry Outlook of Mobikwik IPO

  • Global Market Growth:
    • The global small molecule contract research, development, and manufacturing organization (CRDMO) industry is expected to reach US$159 billion by 2028, representing approximately 53% of the overall global CRDMO industry.
    • Growth is driven by increased outsourcing in pharmaceutical and biotech R&D, along with sustained demand for small molecules.
  • Demand for Cost-Effective Solutions:
    • Rising demand for affordable drugs is a key factor propelling growth in the CRDMO industry.
  • Indian Market Growth:
    • The Indian CRDMO market has been one of the fastest-growing in the Asia-Pacific region, showing significant growth from 2018 to 2023.
    • Projected to grow at a CAGR of 14.0% between 2023 and 2028, the Indian market is expected to reach an estimated value of US$14.1 billion by 2028.
  • Key Drivers in India:
    • Increasing pharmaceutical manufacturing capabilities.
    • Competitive costs in research and manufacturing compared to global peers.
    • Expansion of outsourcing opportunities in drug discovery and development.

Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Sai Life Sciences IPO.

Frequently Asked Questions

What is Sai Life Sciences Ltd IPO?

Answer Field

Sai Life Sciences Ltd IPO is a Mainboard IPO of 5,54,21,124 equity shares of a face value of ₹1 aggregating up to ₹3042.62 Crores. The issue is priced at ₹522 to ₹549 per share. The minimum order quantity is 27 Shares. The IPO opens on December 11, 2024, and closes on December 13, 2024. KFin Techologies Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Sai Life Sciences Ltd IPO will open?

Answer Field

The Sai Life Sciences Ltd IPO opens on December 11, 2024 and closes on December 13, 2024.

What is the lot size of Sai Life Sciences Ltd?

Answer Field

Sai Life Sciences Ltd lot size is 27 shares, and the minimum amount required is ₹14,823.

How to apply for Sai Life Sciences Ltd IPO?

Answer Field

You can apply in Sai Life Sciences Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Sai Life Sciences Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Sai Life Sciences Ltd IPO will be done on December 16, 2024, and the allotted shares will be credited to your demat account by December 17, 2024.

When is Sai Life Sciences Ltd IPO listing date?

Answer Field

The Sai Life Sciences Ltd listing date is December 18, 2024.

Who is the registrar of Sai Life Sciences Ltd IPO?

Answer Field

The registrar of Sai Life Sciences Ltd IPO is KFin Techologies Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

Kotak Mahindra Capital Company Ltd,IIFL Securities Ltd,Jefferies India Pvt Ltd,Morgan Stanley India Company Pvt Ltd will be the book-running lead manager of this IPO.

What is the fresh issue of Sai Life Sciences Ltd IPO?

Answer Field

The fresh issue size is ₹950 Crores equity shares.

What minimum lot size can retail subscribers subscribe to Sai Life Sciences Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 27 shares and ₹14,823 amount.

How can I approve the UPI mandate request for Sai Life Sciences Ltd IPO?

Answer Field

To apply for Sai Life Sciences Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Sai Life Sciences Ltd?

Answer Field

The price of each Sai Life Sciences Ltd share will be ranging in between ₹522 to ₹549 per share.

What is the cut-off time for the UPI mandate for Sai Life Sciences Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, December 13, 2024.

No results found

Browse IPOs

upcoming-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
current-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
  • YASH HIGHVOLTAGE LIMITEDSME IPO

  • Bidding Dates

    12th Dec 2024 - 12th Dec 2024

  • Price Range

    ₹138.0 - 146.0

  • IPO Size

    ₹1,10,01,00,000

  • Apply Now
  • HAMPS BIO LIMITEDSME IPO

  • Bidding Dates

    13th Dec 2024 - 12th Dec 2024

  • Price Range

    ₹51.0 - 51.0

  • IPO Size

    ₹6,22,00,000

  • Apply Now
  • NACDAC INFRASTRUCTURE LIMITEDSME IPO Early Access

  • Bidding Dates

    17th Dec 2024 - 12th Dec 2024

  • Price Range

    ₹33.0 - 35.0

  • IPO Size

    ₹10,01,00,000

  • Apply Now
  • NACDAC INFRASTRUCTURE LIMITEDSME IPO Early Access

  • Bidding Dates

    17th Dec 2024 - 12th Dec 2024

  • Price Range

    ₹33.0 - 35.0

  • IPO Size

    ₹10,01,00,000

  • Apply Now
  • IDENTICAL BRAINS STUDIOS LIMITEDSME IPO Early Access

  • Bidding Dates

    18th Dec 2024 - 12th Dec 2024

  • Price Range

    ₹51.0 - 54.0

  • IPO Size

    ₹19,95,00,000

  • Apply Now
closed-radio
  • IPO Name
  • Bidding Dates
  • Price range
  • IPO Size
  • Lorem Ipsum
  • SWIGGY LIMITEDMainboard IPO

  • Bidding Dates

    6th Nov 2024 - 11th Nov 2024

  • Price Range

    ₹371.0 - 390.0

  • IPO Size

    ₹1,13,27,43,00,000

  • Invest Now
performance-radio
  • IPO Name
  • ISSUE PRICE
  • LISTING DAY CLOSE
  • LISTING DAY(GAIN/LOSS)
  • Lorem Ipsum
  • NTPC GREEN ENERGY LIMITEDMainboard IPO

  • Issue Price

    108.00

  • Listing Day Close

    122.10

  • Listing Day (Gain/Loss)

    12.96

  • ONYX BIOTEC LIMITEDSME IPO

  • Issue Price

    61.00

  • Listing Day Close

    56.75

  • Listing Day (Gain/Loss)

    -6.56

  • ZINKA LOGISTICS SOLUTIONS LIMITEDMainboard IPO

  • Issue Price

    273.00

  • Listing Day Close

    260.20

  • Listing Day (Gain/Loss)

    -4.76

  • MANGAL COMPUSOLUTION LIMITEDSME IPO

  • Issue Price

    45.00

  • Listing Day Close

    42.75

  • Listing Day (Gain/Loss)

    -4.44

  • NEELAM LINENS AND GARMENTS INDIA LIMITEDSME IPO

  • Issue Price

    24.00

  • Listing Day Close

    38.05

  • Listing Day (Gain/Loss)

    58.33

  • NIVA BUPA HEALTH INSURANCE COMPANY LIMITEDMainboard IPO

  • Issue Price

    74.00

  • Listing Day Close

    74.00

  • Listing Day (Gain/Loss)

    0.00

  • SWIGGY LIMITEDMainboard IPO

  • Issue Price

    390.00

  • Listing Day Close

    455.95

  • Listing Day (Gain/Loss)

    16.92

  • ACME SOLAR HOLDINGS LIMITEDMainboard IPO

  • Issue Price

    289.00

  • Listing Day Close

    253.50

  • Listing Day (Gain/Loss)

    -12.11

  • SAGILITY INDIA LIMITEDMainboard IPO

  • Issue Price

    30.00

  • Listing Day Close

    29.36

  • Listing Day (Gain/Loss)

    -3.33

  • AFCONS INFRASTRUCTURE LIMITEDMainboard IPO

  • Issue Price

    463.00

  • Listing Day Close

    474.55

  • Listing Day (Gain/Loss)

    2.59

  • USHA FINANCIAL SERVICES LIMITEDSME IPO

  • Issue Price

    168.00

  • Listing Day Close

    155.85

  • Listing Day (Gain/Loss)

    -7.14

  • GODAVARI BIOREFINERIES LIMITEDMainboard IPO

  • Issue Price

    352.00

  • Listing Day Close

    342.85

  • Listing Day (Gain/Loss)

    -2.56

  • OBSC PERFECTION LIMITEDSME IPO

  • Issue Price

    100.00

  • Listing Day Close

    115.50

  • Listing Day (Gain/Loss)

    16.00

  • UNITED HEAT TRANSFER LIMITEDSME IPO

  • Issue Price

    59.00

  • Listing Day Close

    63.95

  • Listing Day (Gain/Loss)

    8.47

  • DANISH POWER LIMITEDSME IPO

  • Issue Price

    380.00

  • Listing Day Close

    598.50

  • Listing Day (Gain/Loss)

    57.63

  • WAAREE ENERGIES LIMITEDMainboard IPO

  • Issue Price

    1503.00

  • Listing Day Close

    2336.80

  • Listing Day (Gain/Loss)

    55.49

  • DEEPAK BUILDERS AND ENGINEERS INDIA LIMITEDMainboard IPO

  • Issue Price

    203.00

  • Listing Day Close

    161.90

  • Listing Day (Gain/Loss)

    -20.20

  • PREMIUM PLAST LIMITEDSME IPO

  • Issue Price

    49.00

  • Listing Day Close

    48.90

  • Listing Day (Gain/Loss)

    0.00

  • FRESHARA AGRO EXPORTS LIMITEDSME IPO

  • Issue Price

    116.00

  • Listing Day Close

    134.70

  • Listing Day (Gain/Loss)

    16.38

  • LAKSHYA POWERTECH LIMITEDSME IPO

  • Issue Price

    180.00

  • Listing Day Close

    359.10

  • Listing Day (Gain/Loss)

    99.44

We have something for everyone

Explore more Investment options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Related Articles

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text